Twist Bioscience appoints Adam Laponis as CFO effective January 8, 2024

Twist Bioscience Corp

Adam Laponis named CFO, effective Jan 8, 2024; succeeded James Thorburn.
Annual base salary of $450,000; signing bonus $195,000 with clawback if terminated for cause within one year.
Target annual incentive for 2024 at 55% of base salary; equity grant includes 50,000 RSUs (4-yr vest, 1-yr cliff) plus 70,000 shares under exec comp programs.
Laponis previously CFO at Eargo, VP at Tesla, VP/CFO at Cardinal Health, and held roles at Johnson & Johnson.
No family relationships or related-party transactions with Laponis; disclosure via prior 8-K for Thorburn’s departure.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Adam Laponis

Chief Financial Officer

TWST · Twist Bioscience Corp

Effective: 2024-01-08
Filed: January 5, 2024, 6:59 PM ET

On January 5, 2024, Twist Bioscience Corporation (the “Company”) announced the appointment of Adam Laponis as the Company’s Chief Financial Officer and principal financial officer, effective January 8, 2024.

Departed

James Thorburn

Chief Financial Officer

TWST · Twist Bioscience Corp

Effective: 2024-01-08
Successor: Adam Laponis
Filed: January 5, 2024, 6:59 PM ET

As previously reported by the Company in its Form 8-K filed on August 4, 2023 (the “Prior 8-K”), upon commencement of employment by Mr. Laponis, James Thorburn will no longer serve as the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam Laponis was appointed as Chief Financial Officer at Twist Bioscience Corp.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 5, 2024, Twist Bioscience Corporation (the “Company”) announced the appointment of Adam Laponis as the Company’s Chief Financial Officer and principal financial officer, effective January 8, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Thorburn departed as Chief Financial Officer at Twist Bioscience Corp.

Action: will no longer serve
Role: Chief Financial Officer

Exact text from the filing

As previously reported by the Company in its Form 8-K filed on August 4, 2023 (the “Prior 8-K”), upon commencement of employment by Mr. Laponis, James Thorburn will no longer serve as the Company’s Chief Financial Officer.

View on SEC.gov

Twist Bioscience Corp filing history →

Source: SEC EDGAR

accession 0001104659-24-001628

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.